One such gene expression assay, the 21-gene recurrence score (RS), has been demonstrated to add utility to traditional clinicopathologic factors for prognosticating distant recurrence risk and predicting response to adjuvant chemotherapy in patients with early-stage, hormone receptor-positive (HR+) breast cancer [1–3]. The gene discussed is NR4A1; the disease is breast cancer.